Licence and collaboration agreement
Cancer Research Technology Ltd of London, UK, the technology commercialisation arm of the charity Cancer Research UK, has announced a technology licence agreement and collaboration between researchers at University College London (UCL) and Novozymes Delta UK Ltd of Nottingham. The agreement relates to anti-carcinoembryonic antigen single-chain antibody fragment molecules, which will be genetically fused with albumin using Novozymes’ albufuse technology.
Research funded by Cancer Research UK has generated MFE-23, which is a high-affinity single-chain antibody fragment against CEA, the tumor-associated antigen that is expressed in a wide variety of cancers including gastro-intestinal tract, breast, lung and prostate. MFE-23 shows exceptional specificity for tumor-associated CEA.
The albufuse technology is expected to enhance the half-life, bioavailability and efficacy of UCL’s molecules. CRT will be responsible for commercialising any intellectual property that arises from the project, and will seek an industrial partner for onward development of MFE-23.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
